You are here

Ozempic

Akero’s NASH drug combined with Ozempic cut liver fat in small study

Akero’s NASH drug combined with Ozempic cut liver fat in small study

Stat

Akero Therapeutics

Flag link:

Could Pfizer Have an Ozempic Killer on the Way?

Could Pfizer Have an Ozempic Killer on the Way?

Motley Fool

Flag link:

Noom to offer prescriptions for weight-loss drugs

Noom to offer prescriptions for weight-loss drugs

Yahoo Finance

Flag link:

Pfizer Stock Jumps After Diabetes Drug Tops Ozempic In Weight Loss

Pfizer Stock Jumps After Diabetes Drug Tops Ozempic In Weight Loss

Investors Business Daily

clinical trials

Flag link:

‘Robbing Peter to pay Paul’: Obesity experts debate risks of new weight loss drugs

‘Robbing Peter to pay Paul’: Obesity experts debate risks of new weight loss drugs

Stat

Flag link:

Novo Nordisk Seeks to Solidify Its Lead in Diabetes Treatment and Crushing the Market

Novo Nordisk Seeks to Solidify Its Lead in Diabetes Treatment and Crushing the Market

Motley Fool

Flag link:

Most-clicked pharma news for week ending April 1 2023: Signify Health acquisition, Ferring Research Institute shutdown, Jardiance sales increase, and more

Most-clicked pharma news for week ending April 1 2023: Signify Health acquisition, Ferring Research Institute shutdown, Jardiance sales increase, and more

CP Wire

Ferring Pharmaceuticals

Bristol Myers Squibb

Boehringer Ingelheim

Flag link:

Most-clicked pharma news for week ending April 1 2023: Signify Health acquisition, Ferring Research Institute shutdown, Jardiance sales increase, and more

Ferring Pharmaceuticals

Bristol Myers Squibb

Boehringer Ingelheim

Flag link:

The Ozempic Obesity Battle Is Heating Up With Novo Scoring A Fresh Win

The Ozempic Obesity Battle Is Heating Up With Novo Scoring A Fresh Win

Investors Business Daily

Flag link:

Most-clicked pharma news for week ending March 25: PTC Therapeutics CEO retires and Novartis' Zolgensma shows sustained efficacy

Most-clicked pharma news for week ending March 25: PTC Therapeutics CEO retires and Novartis' Zolgensma shows sustained efficacy

CP Wire

PTC Therapeutics

Flag link:

Most-clicked pharma news for week ending March 25: PTC Therapeutics CEO retires and Novartis' Zolgensma shows sustained efficacy

PTC Therapeutics

Flag link:

Six-month Ozempic shortage mostly over after weight-loss craze drained supply

Six-month Ozempic shortage mostly over after weight-loss craze drained supply

Seattle Times, WA

Flag link:

Novo Nordisk comments on role of off-label use in Ozempic shortfall

Novo Nordisk comments on role of off-label use in Ozempic shortfall

Medical Marketing and Media

Flag link:

Novo Nordisk’s Ozempic Shortage Spurs Demand for Eli Lilly’s Diabetes Injection Mounjaro

Novo Nordisk’s Ozempic Shortage Spurs Demand for Eli Lilly’s Diabetes Injection Mounjaro

Xtalks

type 2 diabetes

Flag link:

Just announced: upcoming late-stage clinical trials in weight loss and diabetes

Just announced: upcoming late-stage clinical trials in weight loss and diabetes

Clinical Trials Arena

clinical trials

Flag link:

Novo Nordisk snags high-dose Ozempic approval, turning up the heat on Lilly's Trulicity

Novo Nordisk snags high-dose Ozempic approval, turning up the heat on Lilly's Trulicity

Fierce Pharma

Flag link:

ADA 2021: Novo trumpets higher-dose Ozempic data as Lilly competitors loom

ADA 2021: Novo trumpets higher-dose Ozempic data as Lilly competitors loom

Fierce Pharma

type 2 diabetes

Flag link:

2nd time's the charm? Novo Nordisk reups bid for high-dose Ozempic after March FDA snub

2nd time's the charm? Novo Nordisk reups bid for high-dose Ozempic after March FDA snub

Fierce Pharma

Flag link:

Ahead of potential Ozempic approval in obesity, Novo hits 'full go mode' for launch, exec says

Ahead of potential Ozempic approval in obesity, Novo hits 'full go mode' for launch, exec says

Fierce Pharma

Flag link:

Pages